NCT02174094撤回3 期
Multi-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 9
- 主要终点
- Percent change from baseline to study completion/withdrawal in seizure rate for combined tonic-clonic and clonic seizure rates, based upon a calculation of seizure frequency determined from daily seizure diary counts
研究概览
简要总结
The purpose of this study is to investigate the effect on the frequency of tonic-clonic and clonic seizures of clobazam as adjunctive therapy compared to placebo after 16 weeks of treatment in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 1 Year 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Onset of seizures in the first year of life
- •History of fever-induced prolonged seizures as determined by the Investigator
- •These may include prolonged (approximately 15 minutes or longer) hemi-clonic seizures
- •Multiple seizure types which may include:
- •generalised tonic-clonic (required for inclusion)
- •clonic (required for inclusion)
- •myoclonic jerks/seizures
- •history of normal development prior to seizure onset followed by development delay or regression after seizure onset
- •abnormal EEG consistent with Dravet Syndrome
- •The patient has a history of approximately 2 tonic-clonic or clonic seizures in 2 weeks
- •The patient is treated with at least 1 but no more than 3 antiepileptic drugs (AEDs) [Vagal Nerve Stimulator (VNS) and ketogenic diet will not be considered an AED]
- •Patient has at least 2 seizures during the Baseline Period of either 2 or 4 weeks
排除标准
- •The patient is taking stiripentol, verapamil, or felbatol. If patients have taken these drugs in the past, they need to have been off drug for 5 half-lives
- •The patient is taking a sodium channel blocker including, but not limited to, phenytoin, fosphenytoin, carbamazepine, oxcarbamazepine, lamotrigine, lacosamide, and rufinamide. If patients have taken these drugs in the past, they need to have been off drug for 5 half-lives
- •The patient is on cannabidiol, medical marijuana, or any drug that contains cannabinoids
- •The patient has received chronic treatment (≥2 weeks for any indication) with a benzodiazepine within at least 5 half-lives prior to screening. Rescue therapy for prolonged seizures is allowed
- •The patient has received clobazam within 3 months prior to the Screening Visit. If the patient has received clobazam in the past, discontinuation must not have been for adverse events or lack of efficacy
- •Other protocol-defined inclusion and exclusion criteria may apply.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
干预措施: Placebo (Drug)
Clobazam
Experimental
Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
干预措施: Clobazam (Drug)
结局指标
主要结局
Percent change from baseline to study completion/withdrawal in seizure rate for combined tonic-clonic and clonic seizure rates, based upon a calculation of seizure frequency determined from daily seizure diary counts
时间窗: Baseline and from week 0 to week 16
次要结局
- Percent change in seizure rate for myoclonic seizures determined from daily seizure diary counts(Baseline and from week 0 to week 16)
- Percent change in seizure rate for atypical absence seizures determined from daily seizure diary counts(Baseline and from week 0 to week 16)
- Percentage of initial treatment responders who returned to their baseline tonic-clonic and clonic seizure rate during the study (an assessment of tachyphylaxis)(Baseline and from week 0 to week 16)
- Percent change from baseline to study completion/withdrawal in seizure rate for combined tonic-clonic and clonic seizure rates, based upon a calculation of seizure frequency determined from daily seizure diary counts during 4 weeks of maintenance(Baseline and from week 4 to week 16)
- Percent change in seizure rate for myoclonic seizures determined from video EEG(Baseline and from week 0 to week 16)
- Percent change in seizure rate for atypical absence seizures determined from video EEG(Baseline and from week 0 to week 16)
- Change in Symptom and Seizure Activity Scale (Investigator and Parent/caregiver versions)(Baseline and from week 0 to week 16)
- Number of Participants with Adverse Events of special interest as a Measure of Safety and Tolerability based on dose(Baseline and Week 32)
- Percent change in seizure rate for complex partial seizures determined from daily seizure diary counts(Baseline and from week 0 to week 16)
- Percent change in seizure rate for all seizure types determined from daily seizure diary counts(Baseline and from week 0 to week 16)
- Number of initial treatment responders who returned to their baseline tonic-clonic and clonic seizure rate during the study (an assessment of tachyphylaxis)(Baseline and from week 0 to week 16)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(Up to Week 32)
- Columbia Suicide Severity Rating Scale (C-SSRS), categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories (1, 2, 3, 4 and 7) for patients aged ≥ 6 years(Baseline and from week 0 to week 16)
- Change in Vineland Adaptive Behaviour Scale (VABS) - all adaptive behavior sub-domains and maladaptive behaviors(Baseline and from week 0 to week 16)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
3 期
Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.InfertilityNCT00335725IBSA Institut Biochimique SA151
已完成
2 期
Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonParkinson DiseaseNCT03103399Bial - Portela C S.A.254
已完成
2 期
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive PatientsHypertensionNCT00939588Novartis Pharmaceuticals88
终止
2 期
Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After StrokeHemiplegiaStrokeNCT01311271Seoul National University Bundang Hospital2
已完成
3 期
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes MellitusDiabetic Macular EdemaNCT01171976Novartis Pharmaceuticals373